Featured Research

from universities, journals, and other organizations

Traits Of Aggressive Form Of Prostate Cancer Identified

Date:
June 11, 2008
Source:
University of Michigan Health System
Summary:
Researchers have identified traits of an aggressive type of prostate cancer that occurs in about 10 percent of men who have the disease. They hope the discovery could lead, possibly within the next few years, to a simple urine test that will help to diagnose this variation of prostate cancer.

Researchers led by a team at the Michigan Center for Translational Pathology at the University of Michigan Health System have identified traits of an aggressive type of prostate cancer that occurs in about 10 percent of men who have the disease. They hope the discovery could lead, possibly within the next few years, to a simple urine test that will help to diagnose this variation of prostate cancer.

Related Articles


Previous studies by this group of researchers have shown that most prostate cancer is caused in part by a gene fusion -- the merging of two unrelated genes, which plays a role in at least 50 percent of prostate cancer cases.

To shed light on the prostate cancers that don't involve gene fusion, the researchers in the current study analyzed data on 1,800 prostate cancers to find commonalities in their genetic aberrations. They learned that a gene called SPINK1 (serine peptidase inhibitor, Kazal type 1) was over-expressed, or found in excess amounts, in prostate cancers that do not have gene fusions. The finding suggests that SPINK1 is a biomarker -- a molecule in bodily fluids, blood and tissue that can be a signal of a disease -- for a subtype of prostate cancer.

The findings also suggest that men with SPINK1--related prostate cancers tend to have a quicker recurrence of the disease than those with other types of prostate cancer.

"Our study is really the first to look at what is happening molecularly with fusion-negative prostate cancers," says Scott Tomlins, Ph.D., first author of the paper and an M.D./Ph.D. student at the U-M Medical School.

"Because SPINK1 can be found non-invasively in urine, a test could be developed that would complement current urine testing that is used to detect some prostate cancer or future urine tests for gene fusions," adds senior author Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Endowed Professor of Pathology at the U-M Medical School.

An estimated 186,320 new cases of prostate cancer will be diagnosed this year, according to the National Cancer Institute, and more than 28,000 men will die from the disease this year. More than 70 percent of men diagnosed with prostate cancer are older than 65.

Current tests for prostate cancer include prostate-specific antigen (PSA) blood tests. Increased levels of PSA can indicate that prostate cancer is present. Another test is a digital rectal examination, which can detect abnormalities in the prostate. Another urine-based test screens for PCA3 as a specific biomarker of prostate cancer.

Background: In 2005, Chinnaiyan and his team made the landmark discovery that in prostate cancer, pieces of two chromosomes trade places with each other. This switch, or translocation, causes two unrelated genes to be placed next to each other and fuse together. The abnormal gene fusion associated with prostate cancer occurs when one of two genes, ERG or ETV1, merges with a prostate-specific gene called TMPRSS2.

Before this discovery, it was thought that gene fusions only occurred in blood cancers, such as leukemias and lymphomas, but not in common solid tumors such as prostate cancer. Chinnaiyan's discovery demonstrated that these gene fusions could be found in solid tumors and has opened an entire field of research. This discovery may lead to better diagnostic tests and new treatments for prostate cancer.

Earlier this year, Chinnaiyan's team published a study about a urine test that more accurately detects prostate cancer than any other screening method currently in use. They built on the PCA3 test by screening for six additional biomarkers and some molecules. In their research, the team accurately identified 80 percent of patients who were later found to have prostate cancer, and they were 61 percent effective in ruling out disease in other study participants.

Methodology: In the current study, the team used a bioinformatics analysis method called Cancer Outlier Profile Analysis (COPA) developed by Tomlins and Daniel Rhodes, Ph.D., in Chinnaiyan's laboratory. COPA makes it possible for researchers to detect extremely high expression levels of outlier genes, or genes with characteristics outside the norm.

Using data from seven studies, they found SPINK1 was over-expressed in prostate cancer when compared to benign prostate cells, and that it was found exclusively in cancers that did not involve ERG or ETV1 gene fusions.

Authors: In addition to Tomlins, Chinnaiyan and Rhodes, U-M researchers were from the Comprehensive Cancer Center, Michigan Center for Translational Pathology, Center for Computational Medicine and Biology, Department of Urology, Department of Biostatistics at the U-M School of Public Health, and the Howard Hughes Medical Institute.

In addition to the U-M research team, authors of the paper are from Brigham and Women's Hospital; Harvard Medical School; Dana-Farber Cancer Institute; Institute of Pathology, University, Hospitals Ulm, Germany; Örebro University Hospital, Sweden; Karolinska Institutet, Stockholm, Sweden; Memorial Sloan-Kettering Cancer Center; Helsinki University Central Hospital, Finland; and University Hospital UMAS, Lund University, Malmö, Sweden.

The study and researchers are supported by the Department of Defense, National Institutes of Health, Early Detection Research Network, Prostate Cancer Foundation, Clinical Translational Research Award from the Burroughs Wellcome Foundation, Medical Scientist Training Program, SPORE from the National Cancer Institute, and numerous international organizations.

Disclosure: U-M has filed for a patent on prostate cancer gene fusions and SPINK1 as biomarkers of prostate cancer on which Chinnaiyan, Tomlins, Rhodes and Rohit Mehra are named as inventors. This technology has been licensed to Gen-Probe Inc. to develop molecular diagnostics for prostate cancer. Chinnaiyan serves as a consultant to Gen-Probe.

Journal reference: Cancer Cell, June 2008, Vol. 13 Issue 6.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "Traits Of Aggressive Form Of Prostate Cancer Identified." ScienceDaily. ScienceDaily, 11 June 2008. <www.sciencedaily.com/releases/2008/06/080609124557.htm>.
University of Michigan Health System. (2008, June 11). Traits Of Aggressive Form Of Prostate Cancer Identified. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2008/06/080609124557.htm
University of Michigan Health System. "Traits Of Aggressive Form Of Prostate Cancer Identified." ScienceDaily. www.sciencedaily.com/releases/2008/06/080609124557.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins